Pharmaceutical News

RSS

Neutra names new erectile dysfunction supplement as Pure Plus Powermax

Neutra Corp. announced today that its new all-natural erectile dysfunction supplement will be named Turbocharged Pure Plus Powermax.

6 Mar 2012

SSRIs appear to reduce depressive symptoms, fetal head growth during pregnancy

Treating pregnant women with selective serotonin reuptake inhibitors (SSRIs) appears to be associated with fewer depressive symptoms, reduced fetal head growth and a higher risk for preterm birth, but not with a delay in fetal body growth, according to a report published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.

6 Mar 2012

Viewpoints: Statins and diabetes; Frightening tobacco warnings; The U.S. dental crisis

We're overdosing on cholesterol-lowering statins, and the consequence could be a sharp increase in the incidence of Type 2 diabetes. This past week, the Food and Drug Administration raised questions about the side effects of these drugs and developed new labels for these medications that will now warn of the risk of diabetes and memory loss.

6 Mar 2012

Children's academic achievement test scores not affected by intrauterine drug exposure

Researchers from Boston University Schools of Medicine (BUSM) and Public Health along with Boston Medical Center have found children's academic achievement test scores not affected by intrauterine exposure to cocaine, tobacco or marijuana.

6 Mar 2012

Russia should abandon 'zero-tolerance' approach to drug use and implement proven prevention strategies

Why have effective, "simple tools such as Medication Assisted Therapy and clean needle-exchange services" -- methods that are "very effective in decreasing drug abuse and reducing risk of infection with HIV, hepatitis C and other diseases" – "had so little impact on the policies and programs of the Russian Federation?" Bertrand Audoin, executive director of the International AIDS Society, and Chris Beyrer, a professor at the Johns Hopkins Bloomberg School of Public Health, write in this New York Times opinion piece.

6 Mar 2012

Cenderitide may preserve cardiac function after heart attack

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), has awarded a $2.5 million grant to Mayo Clinic's Cardiorenal Research Laboratory to conduct a highly innovative research project, "Cardiovascular Peptides and Myocardial Infarction."

6 Mar 2012

Microneedle vaccine patches may effectively protect against flu

Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune responses by the Emory and Georgia Tech research team helps explain why the skin is such fertile ground for vaccination with these tiny, virtually painless microneedles.

6 Mar 2012

Young children more likely to be diagnosed and treated for ADHD

The youngest children in the classroom are significantly more likely to be diagnosed with attention-deficit/hyperactivity disorder (ADHD) - and prescribed medication - than their peers in the same grade, according to a study just published in CMAJ.

6 Mar 2012

Prazosin drug shows promise against PTSD-related nightmares

Mayo Clinic researchers this week will announce the use of the blood pressure drug prazosin as an effective treatment to curb post- traumatic stress disorder (PTSD)-related nightmares.

6 Mar 2012

ADHD medication use more prevalent among school-age children

A new study from the Universit- de Montr-al shows an increase in prevalence of Canadian children diagnosed with attention-deficit hyperactivity disorder (ADHD) and in the use of medications associated with ADHD in school-age children.

6 Mar 2012

FDA accepts Eisai's resubmission of perampanel NDA for review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.

5 Mar 2012

Merck fails to get FDA nod for new cholesterol lowering combo pill

The length of delay in approval is not clear yet as the FDA has called for additional study data on the compound. It combines generic Lipitor (Atorvastatin), the top-selling drug of all time, with Merck's cholesterol medicine Zetia (Ezetimibe).

5 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

Repligen seeks EMA marketing approval for SecreFlo for pancreatic imaging

Repligen Corporation announced today that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for SecreFlo to improve detection of pancreatic duct abnormalities in patients with pancreatitis.

5 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

X-rays help decipher how natural antibiotics defy a longstanding set of chemical rules

Researchers working at the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory have used powerful X-rays to help decipher how certain natural antibiotics defy a longstanding set of chemical rules - a mechanism that has baffled organic chemists for decades.

4 Mar 2012

Mylan comments on patent infringement ruling against Sunovion's Brovana

Mylan Inc. today commented on a ruling for partial summary judgment in its patent infringement lawsuit against Sunovion Pharmaceuticals Inc. in relation to Sunovion's Brovana product.

3 Mar 2012

New pharma code expands guidelines for interactions with health care providers

A new practice code for pharmaceutical companies now covers all interactions with health care professionals and bans them from giving payments to doctors to attend conferences.

3 Mar 2012